




Version 1 ▼

Jul 10, 2022

Protocol: HLA-DQB1*0301, HLA-DQB1*0501, and HLA-DQA1*0301 and Their Role in Scleroderma- A Systematic Review V.1

Dylan Thibaut^{1,2,3}, Jared Lehman^{1,2}, Alexis Marquess¹, Kersten Schroeder³¹Lake Erie College of Osteopathic Medicine- Bradenton; ²AdventHealth- Sebring;³University of Central Florida

1 Works for me



Share

dx.doi.org/10.17504/protocols.io.j8nlkqpql5r/v1 Dylan Thibaut

ABSTRACT

Scleroderma remains a debilitating autoimmune condition with immunological linkage to HLA sequences remaining open for further explanation. Through understanding the linkage of specific HLAs to scleroderma, the immunological processes behind the condition can be elucidated. HLA meta-analysis with scleroderma offers a prognostic application to best interpret the odds of scleroderma given a specific HLA. We hope to conduct a meta-analysis to determine how HLA-DQB1*0301, HLA-DQB1*0501, and HLA-DQA1*0301 are linked with scleroderma.

DOI

dx.doi.org/10.17504/protocols.io.j8nlkqpql5r/v1

PROTOCOL CITATION

Dylan Thibaut, Jared Lehman, Alexis Marquess, Kersten Schroeder 2022.
Protocol: HLA-DQB1*0301, HLA-DQB1*0501, and HLA-DQA1*0301 and Their
Role in Scleroderma- A Systematic Review . **protocols.io**
<https://dx.doi.org/10.17504/protocols.io.j8nlkqpql5r/v1>



LICENSE

————— This is an open access protocol distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited

CREATED

Jul 07, 2022

LAST MODIFIED

Jul 10, 2022

PROTOCOL INTEGER ID

66149

Administrative Information

1 Title

Protocol: HLA-DQB1*0301, HLA-DQB1*0501, and HLA-DQA1*0301 and Their Role in Scleroderma- A Systematic Review

2 Registration

Registration is via protocols.io

3 Authors

Dylan Thibaut: Lake Erie College of Osteopathic Medicine - Bradenton, AdventHealth- Sebring, University of Central Florida

ORCID: <https://orcid.org/0000-0002-8739-9688>

Jared Lehman: Lake Erie College of Osteopathic Medicine - Bradenton, AdventHealth- Sebring

ORCID: <https://orcid.org/0000-0001-7524-9175>

Alexis Marquess: Lake Erie College of Osteopathic Medicine - Bradenton

ORCID: <https://orcid.org/0000-0001-6799-9072>

Principle Investigator

Dr. Kersten T Schroeder, PhD: University of Central Florida

ORCID: <https://orcid.org/0000-0002-8412-323X>

4 Amendments

None

5 Support

Sources: No financial sources used

Sponsor: Lake Erie College of Osteopathic Medicine- Bradenton

Role of Sponsor: to facilitate ethical research and oversee the research process from start to end

Introduction

6 Rationale

Scleroderma remains a debilitating autoimmune condition with immunological linkage to HLA sequences remaining open for further explanation. Through understanding the linkage of specific HLAs to scleroderma, the immunological processes behind the condition can be elucidated. In addition, HLA meta-analysis with scleroderma offers a prognostic application to best interpret the odds of scleroderma given a specific HLA.

7 Objectives

We hope to conduct a meta-analysis to determine how HLA-DQB1*0301, HLA-DQB1*0501, and HLA-DQA1*0301 are linked with scleroderma.

Methods

8 Eligibility criteria

Only studies between 1995 and 2022 are included.

9 Information sources

Google Scholar and Pubmed will be accessed during the duration of the study to gather data.

10 Study records

10.1 Data management

Data will be collected by two researchers and will be compiled on a document.

10.2 Selection process

To be included, articles must: contain odds ratio (or enough data to calculate it), be in English, and must use living human test subjects.

Inadequate information for meta-analysis, studies with flawed design, or meta-analyses on the same HLAs are not included.

10.3 Data collection process

Two researchers will individually find and compare studies for inclusion. If in disagreement, researchers will present the study to the PI for the PI to make the final decision on whether to include the information.

11 Data Items

Data collected will include case numbers, control numbers, associated p values if available, the samples studied, odds ratios, confidence intervals, and the name as well as year of the

study examined.

- 12 Outcomes and prioritization
HLA-DQB1*0301, HLA-DQB1*0501, and HLA-DQA1*0301 will specifically be examined.

- 13 Risk of bias in individual studies
The NIH Quality Assessment of case-control studies tool will be used for risk of bias assessment as well as a generated DOI plot.

Data Synthesis

- 14 15a: Data will be examined using Revman 5.4 and/or MetaXL as needed.

- 15 15b: I^2 will be used as a method of examining heterogeneity.

- 16 15c: MetaXL or Revman 5.4 are used if needed for sensitivity analysis.

- 17 15d: Quantitative synthesis is appropriate.

Meta-bias and Confidence

- 18 Meta-bias and confidence in cumulative evidence
GRADE criteria will be used.

19